BOARD OF DIRECTORS


Jon Edwards, PhD

Non-executive Director


Jon Edwards is a Partner at Medicxi, with a primary focus on early-stage opportunities.

Read more...
Prior to Medicxi, Jon worked at Index as an associate and was a life science strategy consultant at ClearView Healthcare Partners. In addition to being a board member for Xenikos, Jon also serves on the boards of Palladio Biosciences, Z-Factor, UltraHuman Ltd, Sydnexis and Impact Biomedicines (acquired by Celgene) and acts as an observer on the boards of Capella Bioscience and Apcintex. Jon holds a PhD in biochemistry and biophysics from the University of North Carolina at Chapel Hill and conducted postdoctoral research at MIT.

Jake Simson, PhD

Non-executive Director


Jake Simson is a Principal on the investment team at RA Capital Management, where...

Read more...
…his primary responsibility is to conduct due diligence on biotechnology companies. Prior to this role, Jake was a Senior Associate on the Landscape Team within the TechAtlas division of RA Capital, where he mapped competitive landscapes in the solid tumor oncology space and performed in-depth analyses of pharma pipelines. In addition to being a board member of Xenikos, Jake also acts as an observer on the board of Arvinas. Jake holds a BS in materials science and engineering from MIT and a PhD in biomedical engineering from Johns Hopkins University. In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels.

Rogier van den Braak, CPA

Non-executive Director


Rogier van den Braak is Chief Financial Officer at Sanquin, where he is responsible for innovation...

Read more...
…and international business development, in addition to his financial duties. Prior to this role, he held various positions of increasing responsibility at Sanquin. Before that, Rogier served as audit manager of the municipality of Amsterdam. In addition to serving as a board member for Xenikos, Rogier also serves as a supervisory board member of ETB-BISLIFE and as director and member of the investment advisory committee of the Landsteiner Foundation for Blood Transfusion Research. Rogier holds an MS in business economics from the VU University of Amsterdam and is also registered as a Chartered Public Accountant in the Netherlands.

Ypke van Oosterhout, PhD

Founder and Chief Executive Officer


Ypke van Oosterhout is the Founder and CEO of Xenikos BV and the pioneering scientist behind...

Read more...
…T-Guard®’s development. Ypke discovered T-Guard while working in the Hematology Department of Radboud University Medical Center (Nijmegen, the Netherlands) after earning his MSc in biology from the University of Nijmegen. Recognizing T-Guard’s clinical potential, Ypke focused his PhD study on its mode of action, safety and efficacy.

On the basis of early positive clinical results, Ypke was awarded a STIGON Grant from the Dutch government initiative supporting entrepreneurship and research into innovative medicines, to continue exploring the clinical and commercial potential of T-Guard.  T-Guard was further developed at Immunotoko BV, a company founded by Ypke with the Radboudumc and Henogen (now Novasep Belgium). Ypke then founded Xenikos BV in 2009 to continue the development of T-Guard through registration for marketing approval as an orphan drug for the treatment acute Graft-Versus-Host Disease (aGVHD), as well as other indications.

Francesco De Rubertis, PhD

Board Observer


Francesco De Rubertis is a Partner and co-founder of Medicxi, one of the largest Biotech Venture...

Read more...
…Capital firms in Europe, which was created in January 2016. Having completed his Post Doc at M.I.T. he joined Index Ventures in 1997 to launch the Life Sciences practice. This is where he spearheaded the creation and adoption of the asset-centric investment strategy which had an immediate impact on the success and growth of the firm.

Francesco’s investments include CellZome (acquired by GlaxoSmithKline), Egalet (Nasdaq: EGLT), GenMab (Copenhagen: GEN.CO), GenSight Biologics (Euronext: SIGHT), Micromet (acquired by Amgen), Minerva Neurosciences (Nasdaq: NERV), Molecular Partners (Swiss: MOLN.SW), PanGenetics (acquired by Abbott), Parallele Biosciences (acquired by Affymetrix, Nasdaq: AFFX), Profibrix (acquired by The Medicines Company). 

Francesco received a B.A. in Genetics and Microbiology from the University of Pavia (Italy) and a PhD in Molecular Biology from the University of Geneva (Switzerland) after which he became a postdoctoral scientist at the Whitehead Institute at M.I.T. He is a Chartered Financial Analyst and serves on the main board of the University of Geneva (Switzerland).

In November 2017 Francesco was named in the first “Bloomberg 50” having been nominated, in the Tech & Science sector, as one of the Top 50 entrepreneurs and innovators who helped to define Global Business in 2017. Francesco has served as Board Observer for Xenikos since 2018.

Derek DiRocco, PhD

Board Observer


Derek DiRocco is a Principal on the Investment Team at RA Capital Management, LLC, a multi-stage...

Read more...
…investment manager dedicated to evidence-based investing in healthcare and life sciences, including companies developing novel drugs, medical devices, and diagnostics. Derek works on both public and private investments and serves as a Board Director for 89Bio, Ltd. Previously, Derek covered solid tumor oncology landscapes. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He conducted his postdoctoral research at Brigham and Women’s Hospital/Harvard Medical School, where he researched the role of the Wnt signaling pathway in mouse models of kidney disease, and was part of a team that discovered a stem cell subtype responsible for solid organ fibrosis.

Derek has been Board Observer for Xenikos since 2018.

Wilko de Vette, MSc

Board Observer


Wilko de Vette is Sector Manager at Oost NL Capital where he is responsible for managing the...

Read more...
…investments in Life Sciences & Medtech.

Prior to this role Wilko gained extensive experience in Finance and Business Transformation as a interim CEO, CRO and CFO. In addition to serving as a Board observer for Xenikos, Wilko also acts as an observer on the Board of InteRNA, Lead Pharma, Alveron Pharma and several other portfolio companies.

Wilko holds a MSc in Finance & Business Economics from the VU University in Amsterdam.

//]]>